Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Expected to Post Quarterly Sales of $165.23 Million

Equities research analysts expect that Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will announce sales of $165.23 million for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have provided estimates for Neurocrine Biosciences’ earnings, with the lowest sales estimate coming in at $151.90 million and the highest estimate coming in at $181.30 million. Neurocrine Biosciences posted sales of $96.91 million in the same quarter last year, which suggests a positive year-over-year growth rate of 70.5%. The firm is scheduled to report its next earnings results on Tuesday, July 30th.

According to Zacks, analysts expect that Neurocrine Biosciences will report full-year sales of $677.99 million for the current financial year, with estimates ranging from $631.00 million to $755.94 million. For the next fiscal year, analysts expect that the firm will post sales of $966.00 million, with estimates ranging from $892.20 million to $1.10 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that follow Neurocrine Biosciences.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Monday, April 29th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.05) by ($0.07). Neurocrine Biosciences had a negative net margin of 7.56% and a negative return on equity of 9.14%. The firm had revenue of $138.40 million for the quarter, compared to analyst estimates of $136.77 million. During the same quarter in the previous year, the company earned ($0.47) EPS. The company’s quarterly revenue was up 94.7% compared to the same quarter last year.

NBIX has been the topic of several research reports. ValuEngine upgraded Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research note on Tuesday, March 19th. BidaskClub cut Neurocrine Biosciences from a “hold” rating to a “sell” rating in a research note on Tuesday, April 23rd. JPMorgan Chase & Co. upgraded Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $100.00 to $106.00 in a research note on Monday, April 22nd. Zacks Investment Research cut Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, April 30th. Finally, Guggenheim initiated coverage on Neurocrine Biosciences in a research note on Tuesday, June 4th. They set a “neutral” rating and a $88.00 price objective on the stock. Six equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $102.16.

In related news, insider Haig P. Bozigian sold 19,297 shares of the firm’s stock in a transaction that occurred on Friday, May 31st. The stock was sold at an average price of $85.02, for a total value of $1,640,630.94. Following the sale, the insider now directly owns 161,273 shares in the company, valued at approximately $13,711,430.46. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Haig P. Bozigian sold 66,667 shares of the firm’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $80.13, for a total value of $5,342,026.71. Following the completion of the sale, the insider now owns 164,415 shares in the company, valued at $13,174,573.95. The disclosure for this sale can be found here. Insiders have sold a total of 142,732 shares of company stock worth $11,388,472 over the last quarter. Insiders own 4.30% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of NBIX. Kore Private Wealth LLC acquired a new stake in Neurocrine Biosciences in the 1st quarter valued at approximately $29,000. Acadian Asset Management LLC acquired a new stake in Neurocrine Biosciences in the 4th quarter valued at approximately $32,000. Golden State Wealth Management LLC acquired a new stake in Neurocrine Biosciences in the 1st quarter valued at approximately $44,000. Quadrant Capital Group LLC increased its position in Neurocrine Biosciences by 9,242.9% in the 1st quarter. Quadrant Capital Group LLC now owns 654 shares of the company’s stock valued at $56,000 after acquiring an additional 647 shares during the period. Finally, Cresset Asset Management LLC acquired a new stake in Neurocrine Biosciences in the 1st quarter valued at approximately $81,000. Hedge funds and other institutional investors own 96.14% of the company’s stock.

Shares of NASDAQ NBIX opened at $83.55 on Thursday. Neurocrine Biosciences has a 52-week low of $64.72 and a 52-week high of $126.98. The company has a market cap of $7.47 billion, a price-to-earnings ratio of 379.77 and a beta of 1.45. The company has a debt-to-equity ratio of 0.96, a quick ratio of 8.61 and a current ratio of 8.79.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.

See Also: Put Option Volume

Get a free copy of the Zacks research report on Neurocrine Biosciences (NBIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply